MOUNTAIN VIEW, Calif. (AP) ¿ Drugmaker Vivus Inc. said Wednesday its obesity drug candidate Qnexa met key weight loss goals in two late-stage studies. Patients taking Qnexa, on average, reduced their weight by up to 14.7 percent in one trial, while the drug also prompted improvement in blood pressure and diabetes risk factors. A second study showed weight loss of about 13.2 percent. In both studies, patients taking placebo lost less than 3 percent of their weight. The studies included more than 3,750 patients taking a mix of three doses and placebo. Vivus said the results support the company's plan to ask for Food and Drug Administration approval by the end of 2009. That could put the company's application ahead of a key competitor, Orexigen Therapeutics Inc.'s Contrave32. In July, La Jolla, Calif.-based Orexigen said the drug met key weight reduction goals in three late-stage studies. Orexigen previously said it plans to ask for FDA approval in early 2010. Elsewhere, San Diego-based Arena Pharmaceuticals Inc. is developing the obesity treatment lorcaserin, which met weight reduction goals in a late-stage study reported in March. There are several other ongoing late-stage studies. Shares of Vivus surged $3.85, or 56 percent, to $10.76 in premarket trading. The stock has ranged from $2.72 to $9 over the past year.
More from Food & Drink
Boston Beer Gets Another Upgrade on Strong Growth of Truly Brand
Boston Beer receives another upgrade, this time from Citi analyst Wendy Nicholson, who boosts her rating on the stock to buy from neutral amid what she sees as 'terrific' growth of its hard seltzer brand, Truly.
Hormel Foods Is Still Attractive With a New Technical Strategy
Let's check out the charts and indicators again on HRL.
Why Hormel Foods CEO Isn't Worried About a Recession
Looking to try some pumpkin spice spam? Hormel Food CEO weighs in on the millennial, pumpkin-spice Spam and why he's not worried about a recession.
Domino's Analysts, Post-Earnings: Things Could Get Worse. Here's What to Weigh.
When considering Domino's stock, investors must study two key matters. One's negative, the other positive.